Galapagos NV and Gilead Sciences closed a global license and collaboration agreement for the global development and commercialization of filgotinib in inflammatory diseases, establishing an upfront license fee payment of $300 million by Gilead to Galapagos. Gilead also made a $425 million equity investment in Galapagos.

Under the terms of the agreement, the companies will collaborate jointly on the global development of filgotinib starting with the initiation of Phase 3 trials in rheumatoid arthritis (RA). Galapagos will co-fund 20% of global development activities and Gilead will be responsible for manufacturing and worldwide marketing and sales activities. Galapagos mantained the option to co-promote filgotinib in the UK, Germany, France, Italy, Spain, Belgium, the Netherlands and Luxembourg, in which case the companies will share profits equally.